ABILITA BIO SECURES $7.5 MILLION IN EQUITY FINANCING FROM TWO BEAR CAPITAL
Summary
It is a novel and elegant approach that overcomes key technical hurdles that are currently impeding the development of therapeutics for challenging targets," said Rachel Tsunemoto Hislop, PhD, a Principal at Two Bear Capital who spearheaded the investment. Currently, the company has four active therapeutic antibody programs and is looking to move its first asset toward the clinical development candidate stage, as well as building partnerships with industry leaders that span from biologics to small molecules.In addition, Dr. Michael Hanson recently joined the Abilita Bio team as CSO. He brings a strong track record of drug discovery and development in the GPCR space and most recently propelled multiple compounds into the clinic during his tenure at ShouTi (now Structure Therapeutics), where he was co-founder and CTO. Two Bear Capital seeks to invest in the most promising early-stage companies solving some of todays most urgent problems at the intersections of healthcare, biotechnology, bioinformatics, artificial intelligence/machine learning, cybersecurity, and software infrastructure for enterprise. To learn more, visit www.twobearcapital.com and follow Two Bear Capital on LinkedIn.Abilita Bio, Inc. is a privately held, innovation-driven biotechnology company focused on discovering and developing therapeutic antibodies targeting the most challenging and medically important multi-span membrane proteins.